Osimertinib responses after disease progression in patients who had been receiving rociletinib

JAMA Oncology

Volumn 2, Issue 4, 2016, Pages 541-543

  Sequist, Lecia V ^a,b   Piotrowska, Zofia ^a,b   Niederst, Matthew J ^a,b   Heist, Rebecca S ^a,b   Digumarthy, Subba ^b,c   Shaw, Alice T ^a,b   Engelman, Jeffrey A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; OSIMERTINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; ROCILETINIB;

CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PIPERAZINES; PYRIMIDINES;

EID: 84986309464     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5009     Document Type: Article

References (6)

1. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-1709.
2. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-1699.
3. Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 2015;5(7):713-722.
4. Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560-562.
5. Gainor JF, Tan DS, De Pas T, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin Cancer Res. 2015;21(12):2745-2752.
6. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.